Hikma stock holds steady after a half year update
Published on 08/19/2026 at 14:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Hikma Pharmaceuticals PLC (GB00B128J450) stock ended at 1,657.50 GBX on August 18, 2026, while the latest market snapshot on August 19, 2026 also showed 1,652.00 GBX with 46.68K shares traded. The company's half year update from August 6, 2026 gave investors a current fundamental backdrop of $1.73 billion in revenue and $1.02 in earnings per share.
Half year numbers
The same August 6 update also showed reported attributable profit slipping while revenue rose, a combination that helps explain why the shares have stayed within a tight band. Hikma's year-to-date move stood at +5.08% in the MarketScreener snapshot on August 19, 2026, which leaves the stock close to flat over five days at +1.50% on the same page.
That mix matters because the company is still trading against a 2026 outlook that was reiterated on April 23, 2026, and the MarketScreener feed also flagged a non-executive purchase on August 12, 2026 alongside other Hikma headlines from August 6, 2026.
What the market is pricing
Analyst expectations in the latest MarketBeat snapshot point to an average 12-month target of GBX 2,060, based on six analysts, with a high of GBX 2,400 and a low of GBX 1,870. Against the August 19 market quote of 1,652.00 GBX on Investing.com, that implies a clear gap between the current level and consensus pricing.
The broader tape is not giving Hikma a strong sector read-through either, with the FTSE-linked stock table on August 19 showing GSK at 1,878.00 GBX, AstraZeneca at 11,874.0 GBX and Hikma at 1,652.00 GBX in the same market view. For investors, the comparison puts Hikma's post-update valuation in context rather than in isolation.
Products and pipeline
Hikma's recent company headlines also point to the operational mix behind the numbers, including a June 22, 2026 FDA approval for Guardant360 Liquid CDx and a June 2, 2026 US launch of tofacitinib oral solution. Those product moves sit alongside the company's broader generic and branded pharmaceuticals base, which is the backdrop for the half year results and the April outlook reaffirmation.
On the trading side, Hikma's August 18 close at 1,657.50 GBX and the August 19 quote at 1,652.00 GBX leave the shares in a narrow range. The market cap line in the available quote set was not surfaced here, but the price action still gives a clean read on sentiment into the next earnings point.
Investor relations
More on Hikma stock and company updates.
Hikma stock price
Hikma stock traded at 1,652.00 GBX on August 19, 2026, after a 1,657.50 GBX close on August 18, 2026.
Company facts
Company: Hikma Pharmaceuticals PLC
ISIN: GB00B128J450
Ticker: HIK
Exchange: LSE
Sector / Industry: Healthcare / Pharmaceuticals
Index membership: FTSE 250
Next earnings date: September 8, 2026
